Details

Autor(en) / Beteiligte

• Medina, Philippe
• Diallo, Khadijetou
• Huc‐Claustre, Emilie
• Attia, Mehdi
• Soulès, Régis
• Silvente‐Poirot, Sandrine
• Poirot, Marc

Titel

The 5,6‐epoxycholesterol metabolic pathway in breast cancer: Emergence of new pharmacological targets

Ist Teil von

• British journal of pharmacology, 2021-08, Vol.178 (16), p.3248-3260

Ort / Verlag

London: Blackwell Publishing Ltd

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• Metabolic pathways have emerged as cornerstones in carcinogenic deregulation providing new therapeutic strategies for cancer management. Recently, a new branch of cholesterol metabolism has been discovered involving the biochemical transformation of 5,6‐epoxycholesterols (5,6‐ECs). The 5,6‐ECs are metabolized in breast cancers to the tumour promoter oncosterone whereas, in normal breast tissue, they are metabolized to the tumour suppressor metabolite, dendrogenin A (DDA). Blocking the mitogenic and invasive potential of oncosterone will present new opportunities for breast cancer treatment. The reactivation of DDA biosynthesis, or its use as a drug, represents promising therapeutic approaches such as DDA‐deficiency complementation, activation of breast cancer cell re‐differentiation and breast cancer chemoprevention. This review presents current knowledge of the 5,6‐EC metabolic pathway in breast cancer, focusing on the 5,6‐EC metabolic enzymes ChEH and HSD11B2 and on 5,6‐EC metabolite targets, the oxysterol receptor (LXRβ) and the glucocorticoid receptor. LINKED ARTICLES This article is part of a themed issue on Oxysterols, Lifelong Health and Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.16/issuetoc ▪▪▪